Q3 2020 Sales Performance

Our RSV assets offer a compelling opportunity for GSK Opportunity is significant Data support move to pivotal studies gsk Older adults Potential first-in-class with differentiated adjuvant 70m adults age 60+ in the US1; >300m in developed regions² -2/3 of older adults in US receive flu or pneumococcal vaccines² Protect infants from birth up to 6 months of life Potential to expand portfolio of other recommended vaccines for pregnant women 4m birth cohort in US³; globally >130m4 Pregnant women ~50% of pregnant women in US receive flu and/or pertussis vaccines5 Compelling neutralising antibodies response and T-cell restoration in older adults; well tolerated Phase 3 start on track for Q1 2021; initial data expected in H2 2022* • Immunogenic response; good safety profile Data in pregnant women in-house and supportive of advancement Maternal phase 3 to start Q4 2020; initial data expected in H2 2022* 1. US Census: https://www.census.gov/data/tables/2018/demo/age-and-sex/2018-older-population.html; 2. CDC: https://www.cdc.gov/nchs/products/databriefs/db281.htm; 3. CDC: https://www.cdc.gov/nchs/nvss/births.htm, 4. United Nations World Population Prospects 2019, 5. CDC: https://www.cdc.gov/vitalsigns/maternal-vaccines/index.html *Timing dependent on RSV infection circulation during pandemic lockdowns. 71

View entire presentation